PMID- 35210509
OWN - NLM
STAT- MEDLINE
DCOM- 20220307
LR  - 20220307
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 12
IP  - 1
DP  - 2022 Feb 24
TI  - Comprehensive geriatric assessment as a useful tool in predicting adverse events 
      in elderly patients with diffuse large B-cell lymphoma.
PG  - 3124
LID - 10.1038/s41598-022-07164-w [doi]
LID - 3124
AB  - We conducted a multicenter prospective study on whether a comprehensive geriatric 
      assessment (CGA) can predict the adverse events (AEs) of chemotherapy in elderly 
      patients with diffuse large B-cell lymphoma (DLBCL). Patients aged >/= 65 years 
      with newly diagnosed DLBCL underwent a pretreatment baseline CGA consisting of 
      six assessment tools: activities of daily living (ADL), instrumental ADL (IADL), 
      mood, nutritional status, comorbidities, and cognitive function. An attending 
      physician chose each patient's treatment but was blind to CGA results. Patients 
      were grouped as "dependent" or "independent" according to the CGA. The primary 
      endpoint was to evaluate the association between chemotherapy-induced grade 3-4 
      toxicity and CGA. Of 86 patients, 78 completed the designated CGA. The median age 
      was 79 years (65-89). Seventy-two patients were treated with a cyclophosphamide, 
      doxorubicin, vincristine, and prednisolone (CHOP-like) regimen, and six were 
      treated with low-toxicity regimens. Forty-one patients were classified as 
      dependent and 37 as independent. In multivariate analysis, an impairment of IADL 
      was independently associated with grade 3-4 leukopenia (odds ratio [OR] 0.63; 95% 
      confidence interval [CI] 0.43-0.92, p = 0.017) and anemia (OR 0.67; 95% CI 
      0.50-0.90, p = 0.008). The presence of a comorbidity was also associated with 
      grade 3-4 non-hematological toxicity (OR 2.17; 95% CI 1.37-3.43, p = 0.001). The 
      4-year survival rate tended to be longer in the independent (72.7%) compared to 
      dependent (56.9%) group. Overall, a CGA may be a useful tool for predicting 
      serious AEs associated with chemotherapy in elderly patients with DLBCL.
CI  - (c) 2022. The Author(s).
FAU - Tanaka, Toshihiro
AU  - Tanaka T
AD  - Division of Oncology, Hematology, and Infectious Diseases, Department of Internal 
      Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, 
      Japan. totanaka@fukuoka-u.ac.jp.
FAU - Sakai, Rika
AU  - Sakai R
AD  - Department of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, 
      241-0815, Japan.
FAU - Choi, Ilseung
AU  - Choi I
AD  - Department of Hematology, National Hospital Organization Kyushu Cancer Center, 
      Fukuoka, 811-1395, Japan.
FAU - Tsukada, Junichi
AU  - Tsukada J
AD  - Department of Hematology, University of Occupational and Environmental Health, 
      Kitakyushu, 807-8555, Japan.
FAU - Sasaki, Hidenori
AU  - Sasaki H
AD  - Division of Oncology, Hematology, and Infectious Diseases, Department of Internal 
      Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, 
      Japan.
FAU - Naito, Yoshiko
AU  - Naito Y
AD  - Division of Oncology, Hematology, and Infectious Diseases, Department of Internal 
      Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, 
      Japan.
FAU - Kiyomi, Fumiaki
AU  - Kiyomi F
AD  - Statistics and Data Center, Clinical Research Support Center Kyushu, Fukuoka, 
      812-8582, Japan.
FAU - Takamatsu, Yasushi
AU  - Takamatsu Y
AD  - Division of Oncology, Hematology, and Infectious Diseases, Department of Internal 
      Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, 
      Japan.
FAU - Tamura, Kazuo
AU  - Tamura K
AD  - Division of Oncology, Hematology, and Infectious Diseases, Department of Internal 
      Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, 
      Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220224
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use
MH  - Comorbidity
MH  - Drug Therapy
MH  - Drug-Related Side Effects and Adverse Reactions/*prevention & control
MH  - Female
MH  - Geriatric Assessment/*methods
MH  - Humans
MH  - Lymphoma, Large B-Cell, Diffuse/drug therapy
MH  - Male
MH  - Prognosis
MH  - Prospective Studies
MH  - Treatment Outcome
PMC - PMC8873456
COIS- Kazuo Tamura received research funding by the following companies: Sanofi KK, 
      Chugai, Nippon Kayaku, ONO, Taiho, Taisho, and Yakult Honsha. The other authors 
      declare that no conflicts of interest exist with regard to the present study.
EDAT- 2022/02/26 06:00
MHDA- 2022/03/08 06:00
PMCR- 2022/02/24
CRDT- 2022/02/25 05:34
PHST- 2021/05/15 00:00 [received]
PHST- 2022/02/14 00:00 [accepted]
PHST- 2022/02/25 05:34 [entrez]
PHST- 2022/02/26 06:00 [pubmed]
PHST- 2022/03/08 06:00 [medline]
PHST- 2022/02/24 00:00 [pmc-release]
AID - 10.1038/s41598-022-07164-w [pii]
AID - 7164 [pii]
AID - 10.1038/s41598-022-07164-w [doi]
PST - epublish
SO  - Sci Rep. 2022 Feb 24;12(1):3124. doi: 10.1038/s41598-022-07164-w.